Published in Nat Med on July 01, 1999
C5a Receptor Expression - COVID-19 (C5-COV) (C5-COV) | NCT04369820
The enigma of sepsis. J Clin Invest (2003) 4.32
Functional roles for C5a receptors in sepsis. Nat Med (2008) 3.33
The role of complement in inflammatory diseases from behind the scenes into the spotlight. Am J Pathol (2007) 3.12
Chemotaxis inhibitory protein of Staphylococcus aureus, a bacterial antiinflammatory agent. J Exp Med (2004) 2.96
The role of the anaphylatoxins in health and disease. Mol Immunol (2009) 2.95
Increased C5a receptor expression in sepsis. J Clin Invest (2002) 1.79
Complement in immune and inflammatory disorders: therapeutic interventions. J Immunol (2013) 1.64
Targeted deletion of HIF-1alpha gene in T cells prevents their inhibition in hypoxic inflamed tissues and improves septic mice survival. PLoS One (2007) 1.61
Intravascular immunity: the host-pathogen encounter in blood vessels. Nat Rev Immunol (2009) 1.60
Role for the alternative complement pathway in ischemia/reperfusion injury. Am J Pathol (2003) 1.49
Protective effects of anti-C5a in sepsis-induced thymocyte apoptosis. J Clin Invest (2000) 1.49
Biological activities of C1 inhibitor. Mol Immunol (2008) 1.46
Novel chemokine responsiveness and mobilization of neutrophils during sepsis. Am J Pathol (2004) 1.42
New insights of an old defense system: structure, function, and clinical relevance of the complement system. Mol Med (2010) 1.37
Role of C3, C5 and anaphylatoxin receptors in acute lung injury and in sepsis. Adv Exp Med Biol (2012) 1.34
Anti-c5a ameliorates coagulation/fibrinolytic protein changes in a rat model of sepsis. Am J Pathol (2002) 1.33
Molecular signatures of sepsis: multiorgan gene expression profiles of systemic inflammation. Am J Pathol (2001) 1.33
The harmful role of c5a on innate immunity in sepsis. J Innate Immun (2010) 1.31
Complement System Part II: Role in Immunity. Front Immunol (2015) 1.31
Functions of the complement components C3 and C5 during sepsis. FASEB J (2008) 1.30
Therapeutic potential of HMGB1-targeting agents in sepsis. Expert Rev Mol Med (2008) 1.30
An essential role for complement C5a in the pathogenesis of septic cardiac dysfunction. J Exp Med (2005) 1.29
Novel insights for systemic inflammation in sepsis and hemorrhage. Mediators Inflamm (2010) 1.24
Neutrophil mobilization from the bone marrow during polymicrobial sepsis is dependent on CXCL12 signaling. J Immunol (2011) 1.21
Inhibition of complement C5a prevents breakdown of the blood-brain barrier and pituitary dysfunction in experimental sepsis. Crit Care (2009) 1.20
Evidence for anti-inflammatory effects of C5a on the innate IL-17A/IL-23 axis. FASEB J (2011) 1.19
C5a enhances dysregulated inflammatory and angiogenic responses to malaria in vitro: potential implications for placental malaria. PLoS One (2009) 1.16
Scientific and clinical challenges in sepsis. Curr Pharm Des (2009) 1.14
Murine complement interactions with Pseudomonas aeruginosa and their consequences during pneumonia. Am J Respir Cell Mol Biol (2003) 1.14
Attenuation of IgG immune complex-induced acute lung injury by silencing C5aR in lung epithelial cells. FASEB J (2009) 1.07
Molecular mechanisms of inflammation and tissue injury after major trauma--is complement the "bad guy"? J Biomed Sci (2011) 1.04
Sepsis, apoptosis and complement. Biochem Pharmacol (2008) 1.01
MyD88-dependent production of IL-17F is modulated by the anaphylatoxin C5a via the Akt signaling pathway. FASEB J (2011) 1.01
C1 inhibitor: biologic activities that are independent of protease inhibition. Immunobiology (2006) 0.98
Increased concentration of the complement split product C5a in acute pyelonephritis during pregnancy. J Matern Fetal Neonatal Med (2005) 0.97
Complement dependency of cardiomyocyte release of mediators during sepsis. FASEB J (2011) 0.96
Complement component C5a mediates hemorrhage-induced intestinal damage. J Surg Res (2008) 0.95
Anaphylatoxins in preterm and term labor. J Perinat Med (2005) 0.95
Deficient IFN signaling by myeloid cells leads to MAVS-dependent virus-induced sepsis. PLoS Pathog (2014) 0.95
Cryptotanshinone inhibits chemotactic migration in macrophages through negative regulation of the PI3K signaling pathway. Br J Pharmacol (2007) 0.94
The C5a receptor antagonist PMX205 ameliorates experimentally induced colitis associated with increased IL-4 and IL-10. Br J Pharmacol (2013) 0.94
Complement activation in emergency department patients with severe sepsis. Acad Emerg Med (2010) 0.94
Complement factor B is the downstream effector of TLRs and plays an important role in a mouse model of severe sepsis. J Immunol (2013) 0.93
Evidence for complement activation in the amniotic fluid of women with spontaneous preterm labor and intra-amniotic infection. J Matern Fetal Neonatal Med (2009) 0.93
Therapeutic potential of targeting IL-17 and IL-23 in sepsis. Clin Transl Med (2012) 0.89
Ron receptor tyrosine kinase-dependent hepatic neutrophil recruitment and survival benefit in a murine model of bacterial peritonitis. Crit Care Med (2008) 0.89
A recombinant vaccine effectively induces c5a-specific neutralizing antibodies and prevents arthritis. PLoS One (2010) 0.88
The augmented neutrophil respiratory burst in response to Escherichia coli is reduced in liver cirrhosis during infection. Clin Exp Immunol (2011) 0.88
Expression and subcellular targeting of human complement factor C5a in Nicotiana species. PLoS One (2012) 0.85
Role of C5 activation products in sepsis. ScientificWorldJournal (2010) 0.85
A novel C5a-neutralizing mirror-image (l-)aptamer prevents organ failure and improves survival in experimental sepsis. Mol Ther (2013) 0.85
Sphingosine kinase 1 mediation of expression of the anaphylatoxin receptor C5L2 dampens the inflammatory response to endotoxin. PLoS One (2012) 0.85
Chlorogenic acid attenuates high mobility group box 1 (HMGB1) and enhances host defense mechanisms in murine sepsis. Mol Med (2013) 0.85
Sepsis and septic shock. Nat Rev Dis Prim (2016) 0.85
Manipulation of the complement system for benefit in sepsis. Crit Care Res Pract (2012) 0.84
Complement C3 and C5 deficiency affects fracture healing. PLoS One (2013) 0.84
Distinct different contributions of the alternative and classical complement activation pathway for the innate host response during sepsis. J Immunol (2011) 0.84
Current views on the mechanisms of immune responses to trauma and infection. Cent Eur J Immunol (2015) 0.83
Complement C3 serum levels in anorexia nervosa: a potential biomarker for the severity of disease? Ann Gen Psychiatry (2011) 0.83
Current and future concepts of abdominal sepsis. World J Surg (2005) 0.83
Beneficial and detrimental effects of plasmin(ogen) during infection and sepsis in mice. PLoS One (2011) 0.83
Complement component 5a receptor oligomerization and homologous receptor down-regulation. J Biol Chem (2008) 0.83
Role of complement in multiorgan failure. Clin Dev Immunol (2012) 0.83
Expression of the C5a receptor (CD88) on granulocytes and monocytes in patients with severe sepsis. Crit Care (2002) 0.83
Renal dysfunction in burns: a review. Ann Burns Fire Disasters (2013) 0.82
C5a regulates IL-12+ DC migration to induce pathogenic Th1 and Th17 cells in sepsis. PLoS One (2013) 0.82
Spatiotemporal dynamics of complement C5a production within bacterial extracellular polymeric substance. J Innate Immun (2013) 0.81
Acute respiratory distress syndrome in the septic surgical patient. World J Surg (2003) 0.81
Cutting edge: critical role for C5aRs in the development of septic lymphopenia in mice. J Immunol (2014) 0.80
The interaction between C5a and sphingosine-1-phosphate in neutrophils for antineutrophil cytoplasmic antibody mediated activation. Arthritis Res Ther (2014) 0.80
Ulex europaeus agglutinin II (UEA-II) is a novel, potent inhibitor of complement activation. Protein Sci (2001) 0.80
New insights for C5a and C5a receptors in sepsis. Front Immunol (2012) 0.79
Complement C5 and early oxygen kinetics during murine sepsis. Acad Emerg Med (2005) 0.79
Activity of lung neutrophils and matrix metalloproteinases in cyclophosphamide-treated mice with experimental sepsis. Int J Exp Pathol (2004) 0.79
Carboxypeptidase B2 deficiency reveals opposite effects of complement C3a and C5a in a murine polymicrobial sepsis model. J Thromb Haemost (2015) 0.78
Is the function of alveolar macrophages altered following blunt chest trauma? Langenbecks Arch Surg (2011) 0.78
Therapeutic interventions in sepsis: current and anticipated pharmacological agents. Br J Pharmacol (2014) 0.78
The immune system's role in sepsis progression, resolution, and long-term outcome. Immunol Rev (2016) 0.78
Pre-neutralization of C5a-mediated effects by the monoclonal antibody 137-26 reacting with the C5a moiety of native C5 without preventing C5 cleavage. Clin Exp Immunol (2003) 0.78
Ischemia/Reperfusion. Compr Physiol (2016) 0.78
Complement Destabilizes Cardiomyocyte Function In Vivo after Polymicrobial Sepsis and In Vitro. J Immunol (2016) 0.77
Early intra-articular complement activation in ankle fractures. Biomed Res Int (2014) 0.77
PATHOLOGICAL ASPECTS OF THE ANTI-INFLAMMATORY/IMMUNE SUPPRESSIVE RESPONSE IN SEPSIS AND SHOCK. Rec Res Dev Immunol (2003) 0.75
Carbon Monoxide-Releasing Molecule-2 Reduces Intestinal Epithelial Tight-Junction Damage and Mortality in Septic Rats. PLoS One (2015) 0.75
Role of Complement C5 in Experimental Blunt Chest Trauma-Induced Septic Acute Lung Injury (ALI). PLoS One (2016) 0.75
Alteration of complement hemolytic activity in different trauma and sepsis models. J Inflamm Res (2012) 0.75
C5a receptor (CD88) promotes motility and invasiveness of gastric cancer by activating RhoA. Oncotarget (2016) 0.75
Complement and sepsis-induced heart dysfunction. Mol Immunol (2016) 0.75
Complement in Pancreatic Disease-Perpetrator or Savior? Front Immunol (2017) 0.75
Fc microparticles can modulate the physical extent and magnitude of complement activity. Biomater Sci (2017) 0.75
A Pathophysiological Insight into Sepsis and Its Correlation with Postmortem Diagnosis. Mediators Inflamm (2016) 0.75
Alternative Pathway Inhibition by Exogenous Factor H Fails to Attenuate Inflammation and Vascular Leakage in Experimental Pneumococcal Sepsis in Mice. PLoS One (2016) 0.75
Anti-inflammatory interventions-what has worked, not worked, and what may work in the future. Transl Res (2015) 0.75
Assessment of interleukin-17A, C5a and RANTES for early diagnosis of neonatal sepsis - a preliminary study. Cent Eur J Immunol (2017) 0.75
Heme-Exposed Pooled Therapeutic IgG Improves Endotoxemia Survival. Inflammation (2016) 0.75
Further studies on the chemotactic factor of complement and its formation in vivo. Immunology (1966) 7.59
TRAF2-mediated activation of NF-kappa B by TNF receptor 2 and CD40. Science (1995) 6.41
Bacterial factors chemotactic for polymorphonuclear leukocytes. Am J Pathol (1968) 5.77
Endothelial cell gene expression of a neutrophil chemotactic factor by TNF-alpha, LPS, and IL-1 beta. Science (1989) 4.99
A plasmin-split fragment of C'3 as a new chemotactic factor. J Exp Med (1967) 4.94
The deactivation of rabbit neutrophils by chemotactic factor and the nature of the activatable esterase. J Exp Med (1968) 4.79
A neutrophil chemotactic factor from human C'5. J Immunol (1969) 4.46
Role of oxygen-derived free radicals and metabolites in leukocyte-dependent inflammatory reactions. Am J Pathol (1982) 4.38
Leukotactic factor produced by sensitized lymphocytes. Science (1969) 3.95
Mechanisms of the inhibition of chemotaxis by phosphonate esters. J Exp Med (1967) 3.87
Susceptibility of the Bacteroides fragilis group in the United States in 1981. Antimicrob Agents Chemother (1983) 3.83
C5 chemotactic fragments produced by an enzyme in lysosomal granules of neutrophils. J Immunol (1970) 3.75
Cellular and molecular regulation of tumor necrosis factor-alpha production by pentoxifylline. Biochem Biophys Res Commun (1988) 3.63
Adhesion molecules and inflammatory injury. FASEB J (1994) 3.53
Acute immunologic pulmonary alveolitis. J Clin Invest (1974) 3.53
The isolation and partial characterization of neutrophil chemotactic factors from Escherichia coli. J Immunol (1975) 3.50
Intravascular activation of complement and acute lung injury. Dependency on neutrophils and toxic oxygen metabolites. J Clin Invest (1982) 3.49
Vascular endothelial-cadherin is an important determinant of microvascular integrity in vivo. Proc Natl Acad Sci U S A (1999) 3.49
Purification and identification of formyl-methionyl-leucyl-phenylalanine as the major peptide neutrophil chemotactic factor produced by Escherichia coli. J Biol Chem (1984) 3.32
Length of uninterrupted CGG repeats determines instability in the FMR1 gene. Nat Genet (1994) 3.22
The production by antigen-stimulated lymphocytes of a leukotactic factor distinct from migration inhibitory factor. Cell Immunol (1970) 3.17
Partial biochemical characterization of the activated esterase required in the complement-dependent chemotaxis of rabbit polymorphonuclear leukocytes. J Exp Med (1967) 3.15
Genetic locus (ompB) affecting a major outer-membrane protein in Escherichia coli K-12. J Bacteriol (1977) 3.10
The phlogistic role of C3 leukotactic fragments in myocardial infarcts of rats. J Exp Med (1971) 2.95
Chemotoxis of mononuclear cells. J Exp Med (1968) 2.95
Oxygen and carbon dioxide fluxes from barley shoots depend on nitrate assimilation. Plant Physiol (1989) 2.72
Involvement of platelet-endothelial cell adhesion molecule-1 in neutrophil recruitment in vivo. Science (1993) 2.71
The chemosuppression of chemotaxis. J Exp Med (1966) 2.62
Synthesis and degradation of barley nitrate reductase. Plant Physiol (1983) 2.55
Evidence for role of hydroxyl radical in complement and neutrophil-dependent tissue injury. J Clin Invest (1983) 2.52
Root respiration associated with ammonium and nitrate absorption and assimilation by barley. Plant Physiol (1992) 2.51
Role of endothelial-leukocyte adhesion molecule 1 (ELAM-1) in neutrophil-mediated lung injury in rats. J Clin Invest (1991) 2.50
Tissue injury caused by deposition of immune complexes is L-arginine dependent. Proc Natl Acad Sci U S A (1991) 2.49
Neutrophil-dependent acute lung injury. Requirement for P-selectin (GMP-140). J Clin Invest (1992) 2.47
Role of oxygen metabolites in immune complex injury of lung. J Immunol (1981) 2.39
Inheritance of nitrate reductase activity in Zea mays L. Proc Natl Acad Sci U S A (1969) 2.38
Tumor necrosis factor-alpha induction of novel gene products in human endothelial cells including a macrophage-specific chemotaxin. J Biol Chem (1990) 2.37
In vitro and in vivo activity of a lymphocyte and immune complex-dependent chemotactic factor for eosinophils. J Exp Med (1971) 2.36
Complement-derived leukotactic factors in inflammatory synovial fluids of humans. J Clin Invest (1971) 2.35
Neutrophil aggregation and swelling induced by chemotactic agents. J Immunol (1977) 2.26
Cellular localization of interleukin-8 and its inducer, tumor necrosis factor-alpha in psoriasis. Am J Pathol (1991) 2.24
Evidence for soluble immune complexes in the pathogenesis of the glomerulonephritis of quartan malaria. Lancet (1969) 2.22
C3 leukotactic factors produced by a tissue protease. J Exp Med (1969) 2.19
Comparison of Difco ESP and Organon Teknika BacT/Alert continuous-monitoring blood culture systems. J Clin Microbiol (1994) 2.17
Human herpesvirus 6 in salivary glands. Lancet (1990) 2.15
Frequent resistance of clinical group B streptococci isolates to clindamycin and erythromycin. Obstet Gynecol (1998) 2.13
Reduced Accumulation of ABA during Water Stress in a Molybdenum Cofactor Mutant of Barley. Plant Physiol (1989) 2.13
Biochemical demonstration of the activatable esterase of the rabbit netrophil involved in the chemotactic response. J Immunol (1970) 2.12
Most frequent scenario for recurrent Candida vaginitis is strain maintenance with "substrain shuffling": demonstration by sequential DNA fingerprinting with probes Ca3, C1, and CARE2. J Clin Microbiol (1996) 2.11
In vivo damage of rat lungs by oxygen metabolites. J Clin Invest (1981) 2.10
In vivo suppression of NF-kappa B and preservation of I kappa B alpha by interleukin-10 and interleukin-13. J Clin Invest (1997) 2.04
Pulmonary endothelial cell killing by human neutrophils. Possible involvement of hydroxyl radical. Lab Invest (1985) 2.01
Vitamin A antagonizes decreased cell growth and elevated collagen-degrading matrix metalloproteinases and stimulates collagen accumulation in naturally aged human skin. J Invest Dermatol (2000) 1.97
Bleomycin-induced pulmonary fibrosis in the rat: inhibition by indomethacin. Am J Pathol (1979) 1.96
Role for macrophage inflammatory protein-2 in lipopolysaccharide-induced lung injury in rats. J Immunol (1996) 1.95
C5a-induced expression of P-selectin in endothelial cells. J Clin Invest (1994) 1.93
Chemotactic factor inactivator in normal human serum. J Clin Invest (1973) 1.93
Chemotactic factor influences on the aggregation, swelling, and foreign surface adhesiveness of human leukocytes. Am J Pathol (1978) 1.91
Generation of chemotactic activity in rabbit serum by plasminogen-streptokinase mixtures. J Exp Med (1967) 1.90
Leukotactic factors elaborated by virus-infected tissues. J Exp Med (1972) 1.89
Neutropenia induced by systemic infusion of chemotactic factors. J Immunol (1977) 1.89
Molecular and clinical correlations of deletions leading to Duchenne and Becker muscular dystrophies. Neurology (1989) 1.88
Defective regulation of inflammatory mediators in Hodgkin's disease. Supernormal levels of chemotactic-factor inactivator. N Engl J Med (1974) 1.88
Patterns of cigarette sales and lung cancer mortality in some central and eastern European countries, 1960-1989. Cancer (1995) 1.86
Tumor necrosis factor participates in the pathogenesis of acute immune complex alveolitis in the rat. J Clin Invest (1989) 1.86
Genetic similarity of Candida albicans strains from vaginitis patients and their partners. J Clin Microbiol (1993) 1.85
Childhood leukaemia following the Chernobyl accident: the European Childhood Leukaemia-Lymphoma Incidence Study (ECLIS). Eur J Cancer (1992) 1.81
Molecular typing of ampicillin-resistant, non-beta-lactamase-producing Enterococcus faecium isolates from diverse geographic areas. J Clin Microbiol (1992) 1.80
Acute inflammatory pulmonary reactions induced by chemotactic factors. Am J Pathol (1979) 1.79
Multicenter survey of the changing in vitro antimicrobial susceptibilities of clinical isolates of Bacteroides fragilis group, Prevotella, Fusobacterium, Porphyromonas, and Peptostreptococcus species. Antimicrob Agents Chemother (2001) 1.79
Impaired leucotactic responsiveness in a child with recurrent infections. Lancet (1969) 1.78
Selective neutrophil desensitization to chemotactic factors. J Cell Biol (1979) 1.77
Requirement and role of C5a in acute lung inflammatory injury in rats. J Clin Invest (1996) 1.77
Tumor necrosis factor alpha regulates in vivo intrapulmonary expression of ICAM-1. Am J Pathol (1993) 1.74
Leukotactic factors in health and disease. Am J Pathol (1971) 1.71
Impaired neutrophil chemotaxis in patients with juvenile and rapidly progressing periodontitis. J Periodontal Res (1979) 1.70
Inhibition of lung inflammatory reactions in rats by an anti-human IL-8 antibody. J Immunol (1993) 1.68
Neutrophil chemotactic factors and related clinical disorders. Arthritis Rheum (1970) 1.68
Molecular cloning and characterization of DEFCAP-L and -S, two isoforms of a novel member of the mammalian Ced-4 family of apoptosis proteins. J Biol Chem (2000) 1.66
Lung and dermal vascular injury produced by preformed immune complexes. Am Rev Respir Dis (1978) 1.64
Pathogenesis of the granulomatous lung diseases. Am Rev Respir Dis (1984) 1.64
Nitrate reductase-deficient mutants in barley : immunoelectrophoretic characterization. Plant Physiol (1983) 1.64
C5 chemotactic fragment induces leukocyte production of tissue factor activity: a link between complement and coagulation. J Clin Invest (1979) 1.63
Isolation from human serum of an inactivator of bacterial lipopolysaccharide. Am J Pathol (1977) 1.58
Influence of inhibitors of cellular function on chemotactic factor-induced neutrophil aggregation. J Immunol (1977) 1.57
Two distinct chemotactic factor inactivators in human serum. J Immunol (1975) 1.55
Inhibition of in vivo and in vitro neutrophil responses to chemotactic factors by a competitive antagonist. J Immunol (1978) 1.55
Endothelial cell killing by neutrophils. Synergistic interaction of oxygen products and proteases. Am J Pathol (1989) 1.55
Chemotaxis of human eosinophils. Am J Pathol (1969) 1.54
Marked synergism between tumor necrosis factor-alpha and interferon-gamma in regulation of keratinocyte-derived adhesion molecules and chemotactic factors. J Clin Invest (1990) 1.54
Role of C5a in multiorgan failure during sepsis. J Immunol (2001) 1.53
Chemotaxis of rat lymphocytes. J Immunol (1977) 1.53
Enhancement by the complement membrane attack complex of tumor necrosis factor-alpha-induced endothelial cell expression of E-selectin and ICAM-1. J Immunol (1995) 1.53
Role of macrophage inflammatory protein-1 alpha (MIP-1 alpha) in acute lung injury in rats. J Immunol (1995) 1.52